Sign in Subscribe
Charles University

Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Wet Age-Related Macular Degeneration

Strategic Insights

— 1 min read

Research findings have been presented on the efficacy and safety of switching from ranibizumab to brolucizumab in the treatment of wet age-related macular degeneration (wAMD). A multicenter retrospective study included patients aged 50 years with active wAMD, and the results showed that switching to brolucizumab reduced central retinal thickness (CRT), modestly improved or stabilized visual acuity (VA), and decreased injection frequency with acceptable safety.

Key Takeaways:

  • The study included 79 eyes (75 patients) with active wAMD, with a median age of 75.0 years [IQR: 70.0- 80.0].
  • Patients received a median of 12.0 ranibizumab injections [IQR: 8.0- 19.0] before switching to brolucizumab, and 5.0 brolucizumab injections [IQR: 4.0- 6.0] post-switch.
  • Median switch VA was 50.0 letters [IQR: 36.5- 63.0], and CRT was 319.0 mm [IQR: 258.0- 393.0].
  • At 6 months, VA improved to 51.0 [IQR: 38.0- 66.5] (p = 0.0001), and CRT decreased to 255.0 mm [IQR: 216.0- 298.0] (p < 0.01).
  • The study concluded that switching to brolucizumab reduced CRT, modestly improved or stabilized VA, and decreased injection frequency with acceptable safety.
  • Limitations included retrospective design, modest sample size, and exclusion of poor visual outcomes.

Statistics:

  • Median age of patients: 75.0 years [IQR: 70.0- 80.0].
  • Number of patients: 75.
  • Number of eyes: 79.
  • Median number of ranibizumab injections: 12.0 [IQR: 8.0- 19.0].
  • Median number of brolucizumab injections: 5.0 [IQR: 4.0- 6.0].
  • Median VA at switch: 50.0 letters [IQR: 36.5- 63.0].
  • Median CRT at switch: 319.0 mm [IQR: 258.0- 393.0].
  • Number of patients with improved VA at 6 months: 51.0 [IQR: 38.0- 66.5].
  • Number of patients with decreased CRT at 6 months: 255.0 mm [IQR: 216.0- 298.0].

Sources:

  • Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Age-Related Macular Degeneration: Multicenter Real-World Outcomes. Clinical Ophthalmology, 2025,Volume 19(Issue 1):3729-3740. (Clinical Ophthalmology - http://www.dovepress.com/clinical-ophthalmology-journal).

Read more